DIFFERIN EPIDUO Drug Patent Profile

Which patents cover Differin Epiduo, and when can generic versions of Differin Epiduo launch?

Differin Epiduo is a drug marketed by Galderma Labs Lp and is included in one NDA.

The generic ingredient in DIFFERIN EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the adapalene; benzoyl peroxide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Differin Epiduo

A generic version of DIFFERIN EPIDUO was approved as adapalene; benzoyl peroxide by PADAGIS ISRAEL on January 23^rd, 2018.

Summary for DIFFERIN EPIDUO

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DIFFERIN EPIDUO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	DIFFERIN EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	220736-001	May 22, 2026		OTC	Yes	Yes

Last updated: July 6, 2026

Differin Epiduo (adapalene + benzoyl peroxide) investment scenario and patent fundamentals analysis

Executive summary: Differin Epiduo (adapalene 0.1% + benzoyl peroxide 2.5%) is a branded fixed-dose combination acne therapy with U.S. market exclusivity dominated by Orange Book patent coverage and formulation/combination claims rather than biologic-type data exclusivity. For investment and competitive-risk modeling, the key drivers are (1) Orange Book patent fence strength and remaining term for both active-ingredient combination and delivery/formulation patents, (2) likelihood and timing of generic and “AB-rated” combination entry under FDA guidance and ANDA feasibility, (3) whether Paragraph IV challenges are plausible against the listed Orange Book patents, and (4) incremental commercial performance tied to prescriptions, payer coverage, and safety/skin-tolerability management in acne. Without the specific Orange Book patent list, assignees, and expirations, an accurate, term-by-term infringement/entry-risk assessment cannot be completed.